Circulating endothelial progenitor cells, Th1/Th2/Th17-related cytokines, and endothelial dysfunction in resistant hypertension

American Journal of the Medical Sciences

Volumn 339, Issue 2, 2010, Pages 117-122

  Magen, Eli ^a   Feldman, Arie ^a   Cohen, Ziona ^a   Alon, Dora Ben ^a   Minz, Evegeny ^a   Chernyavsky, Alexey ^a   Linov, Lina ^a   Mishal, Joseph ^a   Schlezinger, Menacham ^a   Sthoeger, Zev ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

Author keywords

Dysfunction; Endothelial; Hypertension; Progenitor; Resistant; TGF 1

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; BRACHIAL ARTERY; CONTROLLED ARTERIAL HYPERTENSION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RESISTANT ARTERIAL HYPERTENSION; STEM CELL; SYSTOLIC BLOOD PRESSURE; TH1 CELL; TH17 CELL; TH2 CELL; VASODILATATION;

EID: 77049128056     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181c6a968     Document Type: Article

References (39)

1. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536
2. Daugherty A, Rateri DL. T lymphocytes in atherosclerosis: the yinyang of Th1 and Th2 influence on lesion formation. Circ Res 2002;90: 1039-1040
3. Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev 2007; 6:169-175
4. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004;109:II27-33.
5. Rosenzweig A. Circulating endothelial progenitors-cells as biomarkers. N Engl J Med 2005;353:999-1007.
6. Delva P, Degan M, Vallerio P, et al. Endothelial progenitor cells in patients with essential hypertension. J Hypertens 2007;25:127-132
7. Pirro M, Schillaci G, Menecali C, et al. Reduced number of circulating endothelial progenitors and HOXA9 expression in CD34-cells of hypertensive patients. J Hypertens 2007;25:2093-2099
8. Oliveras A, Soler MJ, Martínez-Estrada OM, et al. Endothelial progenitor cells are reduced in refractory hypertension. J Hum Hypertens 2008;22:183-190
9. Oliveras A, de la Sierra A, Martínez-Estrada OM, et al. Putative endothelial progenitor cells are associated with flow-mediated dilation in refractory hypertensives. Blood Press 2008;17:298-305.
10. Magen E, Mishal J, Paskin J, et al. Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein. J Clin Hypertens 2008;10:677-683
11. Rustemeyer P, Wittkowski W, Jurk K, et al. Optimized flow cytometric analysis of endothelial progenitor cells in peripheral blood. J Immunoassay Immunochem 2006;27:77-88.
12. Corretti MC, Anderson TJ, Benjamin EJ, et al. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265
13. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275:964-967
14. Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood 2005;106:1525-1531
15. Magen E, Viskoper R, Mishal J, et al. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control. Isr Med Assoc J 2004;6:742-746
16. Taddei S, Virdis A, Ghiadoni L, et al. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002;62: 265-284 (Pubitemid 34169434)
17. Muiesan ML, Salvetti M, Paini A, et al. Prognostic role of flowmediated dilatation of the brachial artery in hypertensive patients. J Hypertens 2008;26:1546-1547
18. Calhoun DA. Resistant or difficult-to-treat hypertension. J Clin Hypertens (Greenwich) 2006;8:181-186
19. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-1772
20. Porreca E, Di Febbo C, Mincione G, et al. Increased transforming growth factor-beta production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension 1997;30:134-139
21. Massagué J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990;6:597-641.
22. Sarzani R, Brecher P, Chobanian AV. Growth factor expression in aorta of normotensive and hypertensive rats. J Clin Invest 1989;83: 1404-1408
23. Villarreal FJ, Dillmann WH. Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen. Am J Physiol 1992;262:H1861-6.
24. Ketteler M, Noble NA, Border WA. Increased expression of transforming growth factor-beta in renal disease. Curr Opin Nephrol Hypertens 1994;3:446-452
25. Chae CU, Lee RT, Rifai N, et al. Blood pressure and inflammation in apparently healthy men. Hypertension 2001;38:399-403.
26. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;1:1767-1772
27. Kim KI, Lee JH, Chang HJ, et al. Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ J 2008;72:293-298
28. Watabe T, Yamashita JK, Mishima K, et al. TGF-beta signaling in embryonic stem cell-derived endothelial cells. Methods Mol Biol 2006; 330:341-351
29. Zhu C, Ying D, Zhou D, et al. Expression of TGF-beta1 in smooth muscle cells regulates endothelial progenitor cells migration and differentiation. J Surg Res 2005;125:151-156
30. Wang H, Li M, Lin PH, et al. Fluid shear stress regulates the expression of TGF-beta1 and its signaling molecules in mouse embryo mesenchymal progenitor cells. J Surg Res 2008;150:266-270
31. Pohl U, Holz J, Busse R, et al. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986;8: 37-44.
32. Axelsson KL, Wikberg JE, Andersson RG. Relationship between nitroglycerin, cyclic GMP and relaxation of vascular smooth muscle. Life Sci 1979;24:1779-1786
33. Leask A, Abraham DJ. TGF--signaling and the fibrotic response. FASEB J 2004;18:816-817
34. Ruiz-Ortega M, Ruperez M, Esteban V, et al. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 2003;5: 73-79
35. Watanabe M, Oike M, Ohta Y, et al. Sustained contraction and loss of NO production in TGFbeta1-treated endothelial cells. Br J Pharmacol 2006;149:355-364
36. Stumpf C, Jukic J, Yilmaz A, et al. Elevated VEGF-plasma levels in young patients with mild essential hypertension. Eur J Clin Invest 2009;39:31-36
37. Manabe S, Okura T, Watanabe S, et al. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005;46: 735-739
38. Loomans CJ, Dao HH, van Zonneveld AJ, et al. Is endothelial progenitor cell dysfunction involved in altered angiogenic processes in patients with hypertension? Curr Hypertens Rep 2004;6:51-54
39. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) 2007;112:375-384